A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Alberto A. Chiappori, T. Kolevska, D. R. Spigel, S. Hager, M. Rarick, S. Gadgeel, N. Blais, J. Von pawel, L. Hart, M. Reck, E. Bassett, B. Burington, J. H. Schiller

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

Imetelstat, a novel telomerase inhibitor, failed to improve significantly median PFS and OS as maintenance therapy (±bevacizumab) in advanced NSCLC. Telomere length (TL) biomarker results were consistent with the hypothesis that telomerase inhibition is of greater benefit to patients with tumors possessing shorter telomeres; the patients with shorter TL had a trend toward longer median PFS and OS.

Original languageEnglish (US)
Article numbermdu550
Pages (from-to)354-362
Number of pages9
JournalAnnals of Oncology
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

    Fingerprint

Keywords

  • Biomarker
  • Imetelstat
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Chiappori, A. A., Kolevska, T., Spigel, D. R., Hager, S., Rarick, M., Gadgeel, S., ... Schiller, J. H. (2015). A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Annals of Oncology, 26(2), 354-362. [mdu550]. https://doi.org/10.1093/annonc/mdu550